The role of autoantibodies in the development of scleroderma

Potekaev N.N.; Korsunskaia I.M.; Guseva S.D.; Nevozinskaia Z.A.

doi:https://doi.org/

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Korsunskaia I.M.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Guseva S.D.

Dermatovenerological Dispensary #16, Moscow

Nevozinskaia Z.A.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

The role of autoantibodies in the development of scleroderma

Authors:

Potekaev N.N., Korsunskaia I.M., Guseva S.D., Nevozinskaia Z.A.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2014;12(1): 4‑12

Read: 9262 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Potekaev NN, Korsunskaia IM, Guseva SD, Nevozinskaia ZA. The role of autoantibodies in the development of scleroderma. Russian Journal of Clinical Dermatology and Venereology. 2014;12(1):4‑12. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The literature review focuses on the role of antinuclear antibodies in the diagnosis of scleroderma. There are about 200 antibody species targeted to nucleic acids, histones, nuclear membrane proteins, ribonucleoproteins, nucleolar proteins, and centromeres. The main type of antinuclear antibodies is autoantibodies to Scl-70 antigen (topoisomerases), which are found in systemic sclerosis. Topoisomerase is one of the enzymes involved in the mechanisms of uncoiling of supercoiled DNA required for gene transcription. In 90% of cases of systemic sclerosis, some antinuclear antibodies are identified simultaneously. These are antibodies to centromeres and Th/To, fibrillarin and U3-RNR, U1-RNR, to Ku, B23 and NOR90. The information about antibodies Ro/SS-A to nuclear ribonucleoprotein and single-stranded DNA is presented. The detailed analysis of the clinical significance of the detection of antibodies in patients with connective tissue diseases is provided.

Keywords:

scleroderma

antinuclear antibodies

anticentromere antibodies

autoantibodies to topoisomerase I and II

antihistone antibodies

antibodies to single-stranded DNA

anti-U3-RNP antibodies

Authors:

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Korsunskaia I.M.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Guseva S.D.

Dermatovenerological Dispensary #16, Moscow

Nevozinskaia Z.A.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Close metadata

References:

Wojas-Pelc A., Lipko-Godlewska S. Pathogenesis of skin scleroderma - literature review. Przegl Lek 2005; 62: 5: 310-313.
Schmidt J., Launay D., Soudan B., Hachulla E., de Groote P., Lambert M., Queyrel V., Morell-Dubois S., Hatron P.Y. Assessment of plasma endothelin level measurement in systemic sclerosis. Rev Med Intern 2007; 28: 6: 371-376.
Еl-Azhary R.A., Aponte C.C., Nelson A.M., Weaver A.L., Homburger H.A. Antihistone antibodies in linear scleroderma variants. Int J Dermatol 2006; 45: 11: 1296-1299.
Kulthanan K., Jiamton S., Taiyaitiang C., Pinkaew S., Suthipinittharm P. Direct immunofluorescence study in Thai patients with scleroderma. J Med Ass Thai 2006; 89: 10: 1670-1676.
Magnant J., de Monte M., Guilmot J.L., Lasfargues G., Diot P., Asquier E., Degenne D., Boissinot E., Diot E. Relationship between occupational risk factors and severity markers of systemic sclerosis. J Rheumatol 2005; 32: 9: 1713-1718.
Arnett F.C., Gourh P., Shete S., Ahn C.W., Honey R., Agarwal S.K., Tan F.K., McNearney T., Fischbach M., Fritzler M.J., Mayes M.D., Reveille J.D. Major histocompatibility complex (MHC) class II alleles, haplotypes, and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010; 69: 5: 822-827.
Beşliu A.N., Bănică L.M., Lonescu R., Predeţeanu D., Stăvaru C., Marica C.M., Chiţonu C., Pistol G., Stefănescu M., Matache C. Role of cellular immunity in systemic sclerosis pathogenesis: update on CD4+T cells population studies. Roum Arch Microbiol Immunol 2009; 68: 1: 5-13.
Hanke K., Dähnrich C., Brückner C.S., Huscher D., Becker M., Jansen A., Meyer W., Egerer K., Hiepe F., Burmester G.R., Schlumberger W., Riemekasten G. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthr Res Ther 2009; 11: 1: R28.
Kang M.R., Muller M.T., Chung I.K. Telomeric DNA damage by topoisomerase I. A possible mechanism for cell killing by camptothecin. J Biol Chem 2004; 279: 13: 12535-12541.
Azzouz D.F., Rak J.M., Fajardy I., Allanore Y., Tiev K.P., Farge-Bancel D., Martin M., Kanaan S.B., Pagni P.P., Hachulla E., Harlé J.R., Didelot R., Granel B., Cabane J., Roudier J., Lambert N.C. Comparing HLA shared epitopes in French Caucasian patients with scleroderma. PLoS One 2012; 7: 5: e36870.
Mégarbané H., Tomb R., Makhoul E. Plaque-type scleroderma associated with linear and oesophageal features and facial and extra-facial hemiatrophy. Ann Dermatol Venereol 2007; 134: 1: 68-71.
Admou B., Essaadouni L., Amal S., Arji N., Chabaa L., El Aouad R. Autoantibodies in systemic sclerosis: clinical interest and diagnosis approach. Ann Biol Clin (Paris) 2009; 67: 3: 273-281.
Gryga K., Milewski M., Zółciński M., Dyczek A., Musiał J. Anti-Ku autoantibodies: series of 5 cases. Pol Arch Med Wewn 2009; 119: 1-2: 95-97.
Feki S., Frikha F., Ben Hadj Hmida Y., Abed S., Ben Ayed M., Turki H., Hachicha J., Baklouti S., Bahloul Z., Masmoudi H. Prevalence and diagnostic value of antinuclear antibodies without identified antigenic target: A retrospective study of 90 patients. Rev Med Intern 2012; 33: 9: 475-481.
Hayakawa I., Hasegawa M., Takehara K., Sato S. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum 2004; 50: 1: 227-232.
Takehara K., Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 2005; 44: 3: 274-279.
Bonroy C., Van Praet J., Smith V., Van Steendam K., Mimori T., Deschepper E., Deforce D., Devreese K., De Keyser F. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 2012; 379: 1-2: 53-60.
Narbutt J., Lesiak A., Kwiecień A., Sysa-Jedrzejowska A., Kuydowicz J. Scleroderma-like lesions in the course of autoimmune hepatitis. Case report. Przegl Lek 2005; 62: 5: 314-316.
Arkachaisri T., Fertig N., Pino S., Medsger T.A. Jr. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. J Rheumatol 2008; 35: 12: 2439-2444.
Sato S., Kodera M., Hasegawa M., Fujimoto M., Takehara K. Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol 2004; 151: 6: 1182-1188.
Aggarwal R., Lucas M., Fertig N., Oddis C.V., Medsger T.A. Jr. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60: 4: 1112-1118.
Steen V., Domsic R.T., Lucas M., Fertig N., Medsger T.A. A clinical and serologic comparison of African-American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012; 64: 9: 2986-2994.
Ferreira J.P., Almeida I., Marinho A., Cerveira C., Vasconcelos C. Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol 2012; 2012: 415272. doi: 10.5402/2012/415272.
Mandai S., Arai Y., Hirasawa S., Hirai T., Aki S., Inaba N., Aoyagi M., Tanaka H., Tamura T., Sasaki S. Anti-centromere Antibody-positive Subjects Presenting with Hypertensive Emergency and Renal Dysfunction in the Absence of Skin Manifestations: A Variant of Systemic Sclerosis or a Novel Entity? Intern Med 2012; 51: 12: 1567-1572.
Volpe A., Ruzzenente O., Caramaschi P., Pieropan S., Tinazzi I., Carletto A., Bambara L.M., Biasi D. Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. Rheumatol Int 2009; 29: 9: 1073-1079.
Hudson M., Mahler M., Pope J., You D., Tatibouet S., Steele R., Baron M.; Investigators of the Canadian Scleroderma Research Group, Fritzler M. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012; 39: 4: 787-794.
Saito A., Muro Y ., Sugiura K., Ikeno M., Yoda K., Tomita Y. CENP-O, a protein localized at the centromere throughout the cell cycle, is a novel target antigen in systemic sclerosis. J Rheumatol 2009; 36: 4: 781-786.